Brief: Transgene Says Data From Phase I Trial Shows TG6002 Has Potential For IV Administration

Transgene SA

16/09/2021 07:48

Sept 16 (Reuters) - TRANSGENE SA  TRNG.PA :
    * PRESENTS DATA FROM PHASE I CLINICAL TRIAL CONFIRMING THE
POTENTIAL OF THE ONCOLYTIC VIRUS TG6002
    * AS OF TODAY, DOSE ESCALATION HAS BEEN COMPLETED
    * TRIAL IS CURRENTLY ENROLLING PATIENTS IN ADDITIONAL
COHORTS
ASSESSING SEVERAL ADMINISTRATION SCHEDULES
    * DATA FURTHER CONFIRM THAT TRANSGENE'S DOUBLE DELETED
VV(COP)TK(-)RR(-) PATENTED VIRUS BACKBONE, WHICH FORMS BASIS OF
COMPANY'S INVIR.IO™ PLATFORM, HAS POTENTIAL TO BE GIVEN
INTRAVENOUSLY
    * DATA ALSO DEMONSTRATE THAT CHEMOTHERAPY AGENT 5-FU IS
PRODUCED
IN TUMOR ACROSS THREE DOSE-LEVEL COHORTS

Source text for Eikon:  ID:nBwbK5Nlra 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))